DarioHealth Launches Version 3.5 of its MyDario App to Support iPhone 7 and iPhone 8

CAESAREA, Israel, Nov. 20, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced the availability of update version 3.5 of its MyDario app. The app update includes support for DarioHealth's new Lightning compatible device for iPhone 7 and iPhone 8 which was recently awarded the CE Mark.

The DarioHealth lightning adapter is currently under consideration for regulatory approval with the United States Food and Drug Administration and the Therapeutic Goods Administration (TGA) in Australia.

The 3.5 version update ensures that users will be able to receive the same quality user experience with DarioHealth on the latest Apple devices, including the brand-new iPhone 8.

Erez Raphael, Chairman and CEO of DarioHealth, commented, "From a software perspective, we continue to stay ahead of the technological change curve with behind-the-scene adjustments that pave the way for consumers with iPhone 7 and 8. On the product marketing side, we've worked with our customers to understand their needs, and it is very gratifying to launch a version that introduces several new features which continue to simplify diabetes management."

Amongst the new features that are being rolled out with version 3.5 are a weight log and a barcode scanner. The weight log seamlessly integrates with Dario's intuitive logbook and charts. Now customers have one place where they can see their diabetes snapshot and track their weight.

In addition, customers can now scan foods with the barcode scanner feature in the all-in-one smart diabetes system. This permits easier carb counting, as customers simply point their smartphone at a barcode and the app imports the nutritional information for the particular food. DarioHealth believes this feature will increase customer engagement, and help customers keep better track of their carbohydrate intake.

About DarioHealth Corp.
DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app gives users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional office in Burlington, Massachusetts. For more information, visit http://mydario.investorroom.com/.

Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when it describes pending regulatory approvals for the Lightning adapter and the benefits of the app version update.  Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

DarioHealth Corporate Contact:
Shmuel Herschberg
Marketing Director
[email protected]
1-914-775-5548

DarioHealth Public Relations Contact:
Terese Kelly
Rosica PR
[email protected]
1-201-843-5600

DarioHealth Investor Relations Contact:
Stephen Hart
Hayden IR,
[email protected]
1-917-658-7878

SOURCE DarioHealth Corp.